Established Conditions are elements identified in the marketing authorization dossier that are essential for ensuring product quality, and whose modification triggers a regulatory notification. A Post-Approval Change Management Protocol (PACMP) pre-defines which data will support a specific planned future change and in which reporting category it should be submitted to the authority.
Established Conditions as a Regulatory Boundary
Established Conditions, often referred to simply as Established Conditions, separate the regulatory-relevant parts of CMC information from supporting information. They can refer to manufacturing steps, process parameters, control strategy, specifications, or other quality-defining elements. Their identification should clarify for each product which change requires a regulatory assessment before implementation.
The selection is not based on the length of a dossier section, but on its significance for consistent product quality. For example, in a manufacturing process, critical parameters and their accepted ranges can be part of the Established Conditions, while explanations of the development pathway can be supporting information. The boundary must be described in such a way that it can actually be applied to a later change.
Pre-agreed Change Management Protocol
The Post-Approval Change Management Protocol, often called PACMP, describes a concretely expected change, the study and data plan, and the requested reporting category. Instead of submitting the change only after full development without prior consultation, the scientific justification of the future evidence package is agreed upon regulatorily in advance. It thus creates a defined path for a change, not a blanket permission for arbitrary optimizations.
Such a protocol can be created, for example, for the introduction of a new analytical technology or a foreseeable adjustment of a manufacturing step. Crucially, it determines which comparability data, validations, and acceptance criteria must be demonstrated later. The execution of the change remains bound by the conditions specified in the protocol and the appropriate regulatory submission.
The precise formulation of Established Conditions prevents two opposing errors. If they are too broad, every technical detail unnecessarily becomes a regulatory change; if they are too vague, it remains unclear when the approved control strategy is deviated from. ICH Q12 therefore requires a product- and risk-based identification, which is comprehensibly presented in the drug master file.
A PACMP consists of two interrelated regulatory steps: First, the protocol with its planned data package is submitted, followed later by the notification of the actually implemented change with the agreed results. The data can include comparability studies, process validation, or analytical validation, depending on what the change affects. An unmet acceptance criterion cannot be bypassed by merely invoking the protocol.
For global supply chains, it must also be checked whether a protocol accepted in one region has the same submission pathway in other affected regions. Internal change planning should reflect these regional differences before technical implementation.
Distinction from Internal Change Control
Internal change control within the pharmaceutical quality system evaluates and approves changes within the company or the supply chain. It manages tasks, risks, implementation, and effectiveness review, regardless of whether an authority is involved. Established Conditions and a Post-Approval Change Management Protocol complement this system with the regulatory perspective of the approved dossier.
An internally approved change is therefore not automatically regulatory implementable. First, it is checked whether an Established Condition is affected and which reporting category results from it; for an existing change protocol, it is additionally checked whether the planned change and the available data package meet its framework. The existing term lifecycle management remains broader, while these instruments structure the concrete dossier management of a CMC change.
Relevance for clinical trials
After approval, clinical studies can involve new dosage forms, comparators, supply chains, or manufacturing sites, without losing sight of the approved product quality. If clinical material originates from a process changed after approval, its assignment to the approved conditions and to the clinical documentation must be traceable. This also applies if a study generates data to support a planned future change.
Full-service CROs like Mediconomics support the temporal linkage of CMC changes, regulatory submissions, and the use of investigational medicinal products. They can coordinate data lists for comparability, communication between Regulatory Affairs and the clinical supply chain, and documentation of permissible batch configurations, so that a PACMP strategy does not conflict with operational study supply.
Frequently Asked Questions (FAQ)
Are all details in the marketing authorization dossier Established Conditions?
No. ICH Q12 distinguishes Established Conditions from supporting information. Which elements are considered Established Conditions is determined by their relevance to product quality.
Does a change protocol allow implementation before submission?
No. The protocol pre-defines the future data basis and reporting category. The change is only submitted and implemented according to the agreed regulatory pathway.
Why is internal change control still needed despite PACMP?
Because the PACMP addresses regulatory planning, while the quality system manages the operational implementation, risk analysis, responsibilities, and effectiveness review of the actual change.
Regulatory References
- ICH Q12 “Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management” — defines Established Conditions and Post-Approval Change Management Protocols.
- ICH Q10 “Pharmaceutical Quality System” — describes the pharmaceutical change system as a quality system element.
- EudraLex Volume 4, Annex 15 “Qualification and Validation” — requires the assessment of planned GMP-relevant changes against validated status and control strategy.